Veleva, Nadia, Bulgaria

• Vol 8, No 1 (2022) - Original Article
  Enfortumab vedotin for the treatment of patients with urothelial cancer after failure of the treatment with PD-1/PD-L1 inhibitor—cost-effectiveness analysis
  Abstract  PDF (Bulgarian)